Finance
Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
Chiesi Farmaceutici SpA agreed to acquire US-listed KalVista Pharmaceuticals Inc. for about $1.9 billion in its biggest acquisition to date, expanding the Italian company’s rare immunology portfolio.
B
Bloomberg
April 29, 2026·1 min read
Image: Bloomberg
Chiesi Farmaceutici SpA agreed to acquire US-listed KalVista Pharmaceuticals Inc. for about $1.9 billion in its biggest acquisition to date, expanding the Italian company’s rare immunology portfolio.
Original article
Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
Published by Bloomberg